These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 19623693)
1. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. Nel A; Smythe S; Young K; Malcolm K; McCoy C; Rosenberg Z; Romano J J Acquir Immune Defic Syndr; 2009 Aug; 51(4):416-23. PubMed ID: 19623693 [TBL] [Abstract][Full Text] [Related]
2. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. Romano J; Variano B; Coplan P; Van Roey J; Douville K; Rosenberg Z; Temmerman M; Verstraelen H; Van Bortel L; Weyers S; Mitchnick M AIDS Res Hum Retroviruses; 2009 May; 25(5):483-8. PubMed ID: 19388819 [TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. Nel AM; Smythe SC; Habibi S; Kaptur PE; Romano JW J Acquir Immune Defic Syndr; 2010 Oct; 55(2):161-9. PubMed ID: 20574411 [TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. Nel A; van Niekerk N; Kapiga S; Bekker LG; Gama C; Gill K; Kamali A; Kotze P; Louw C; Mabude Z; Miti N; Kusemererwa S; Tempelman H; Carstens H; Devlin B; Isaacs M; Malherbe M; Mans W; Nuttall J; Russell M; Ntshele S; Smit M; Solai L; Spence P; Steytler J; Windle K; Borremans M; Resseler S; Van Roey J; Parys W; Vangeneugden T; Van Baelen B; Rosenberg Z; N Engl J Med; 2016 Dec; 375(22):2133-2143. PubMed ID: 27959766 [TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. Bunge KE; Dezzutti CS; Rohan LC; Hendrix CW; Marzinke MA; Richardson-Harman N; Moncla BJ; Devlin B; Meyn LA; Spiegel HM; Hillier SL J Acquir Immune Defic Syndr; 2016 Apr; 71(5):498-505. PubMed ID: 26565716 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. Nel AM; Coplan P; Smythe SC; McCord K; Mitchnick M; Kaptur PE; Romano J AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1181-90. PubMed ID: 20854207 [TBL] [Abstract][Full Text] [Related]
8. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365 [TBL] [Abstract][Full Text] [Related]
9. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Woolfson AD; Malcolm RK; Morrow RJ; Toner CF; McCullagh SD Int J Pharm; 2006 Nov; 325(1-2):82-9. PubMed ID: 16884869 [TBL] [Abstract][Full Text] [Related]
10. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. Baeten JM; Palanee-Phillips T; Brown ER; Schwartz K; Soto-Torres LE; Govender V; Mgodi NM; Matovu Kiweewa F; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Pather A; Naidoo L; Husnik M; Richardson BA; Parikh UM; Mellors JW; Marzinke MA; Hendrix CW; van der Straten A; Ramjee G; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Mayo A; Scheckter R; Berthiaume J; Livant E; Jacobson C; Ndase P; White R; Patterson K; Germuga D; Galaska B; Bunge K; Singh D; Szydlo DW; Montgomery ET; Mensch BS; Torjesen K; Grossman CI; Chakhtoura N; Nel A; Rosenberg Z; McGowan I; Hillier S; N Engl J Med; 2016 Dec; 375(22):2121-2132. PubMed ID: 26900902 [TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679 [TBL] [Abstract][Full Text] [Related]
12. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. Gupta KM; Pearce SM; Poursaid AE; Aliyar HA; Tresco PA; Mitchnik MA; Kiser PF J Pharm Sci; 2008 Oct; 97(10):4228-39. PubMed ID: 18338805 [TBL] [Abstract][Full Text] [Related]
13. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093 [TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Moss JA; Malone AM; Smith TJ; Butkyavichene I; Cortez C; Gilman J; Kennedy S; Kopin E; Nguyen C; Sinha P; Hendry RM; Guenthner P; Holder A; Martin A; McNicholl J; Mitchell J; Pau CP; Srinivasan P; Smith JM; Baum MM Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245 [TBL] [Abstract][Full Text] [Related]
15. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Nuttall JP; Thake DC; Lewis MG; Ferkany JW; Romano JW; Mitchnick MA Antimicrob Agents Chemother; 2008 Mar; 52(3):909-14. PubMed ID: 18086845 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. Chen BA; Panther L; Marzinke MA; Hendrix CW; Hoesley CJ; van der Straten A; Husnik MJ; Soto-Torres L; Nel A; Johnson S; Richardson-Harman N; Rabe LK; Dezzutti CS J Acquir Immune Defic Syndr; 2015 Nov; 70(3):242-9. PubMed ID: 26034880 [TBL] [Abstract][Full Text] [Related]
17. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women. Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE; J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401 [TBL] [Abstract][Full Text] [Related]
18. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa. Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505 [TBL] [Abstract][Full Text] [Related]
19. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring. Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM; Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511 [TBL] [Abstract][Full Text] [Related]
20. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides. Holt JD; Cameron D; Dias N; Holding J; Muntendam A; Oostebring F; Dreier P; Rohan L; Nuttall J Antimicrob Agents Chemother; 2015 Jul; 59(7):3761-70. PubMed ID: 25845860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]